Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy
about
Adoptive immunotherapy for cancer: building on successCancer immunotherapy: moving beyond current vaccinesSub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerImplication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allograftsClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesDetection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscopeIn vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsAllogeneic beta-islet cells correct diabetes and resist immune rejection.Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells.T-cell-directed cancer vaccines: the melanoma model.Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.Spinning molecular immunology into successful immunotherapy.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.Prostate cancer as a model for tumour immunotherapy.Synthetic peptides as cancer vaccines.Targeting tumours with genetically enhanced T lymphocytes.Principles of tumor immunosurveillance and implications for immunotherapy.Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantCreating therapeutic cancer vaccines: notes from the battlefieldAnti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic modelExpression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.Challenges and future perspectives of T cell immunotherapy in cancerAn Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia CellsIntratumoral immunotherapy: using the tumour against itself.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsHuman melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigenTNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.Dendritic cell fusion vaccines for cancer immunotherapy.Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.Spontaneous tumor rejection by cbl-b-deficient CD8+ T cellsStimulation of autoimmunity by toll-like receptor ligands.
P2860
Q24546258-AEAE3241-47DA-4A90-BE72-87CF4958D5A9Q24548229-0822C0C8-88D3-4142-AE2C-8F7D40D9B072Q24793123-F9FD5E79-FB74-4BF1-9502-3D664A1F9A63Q26825202-408CDA3C-D808-4619-9CD4-E2DD15E7CE41Q26864603-D950246C-6910-4EB2-9DF3-E6BA55494CF3Q27334728-E1E77823-E138-455A-AA95-14EC6E3FB625Q33178945-11D0A07A-7F31-47F9-8D33-61EBA9B54B4AQ33713362-529279CF-E645-415E-9F56-689453CBFE8FQ33778847-48D0AD90-9457-49CF-AD24-235B5BEA31EAQ33791198-65F64C48-57F6-4E46-B131-F40E278BF3F6Q33815865-5D856F5F-4745-44B0-963C-1ADCB385F10DQ33831940-AA84965D-6196-45C6-959A-89EC0C1D6DC8Q34031934-05DB1618-A7E6-44A1-9127-E3B02CB472DAQ34122445-660BE040-BDA9-40C1-B714-8E8D78815D82Q34208635-F2896837-6416-4B33-93D9-24E82E96998BQ34312635-CC0D4D07-0C6A-480A-A034-00D3C53DCFBBQ34452071-F1123157-B16E-4B1B-8F15-749A14091B89Q34467878-E8CCE3E4-58A1-4F35-A604-01941D43C575Q34632056-CCA4C05F-806D-43A7-AF08-424755354BE5Q34755544-DACC02EE-F12E-4B09-B60E-A9B567CEEC6CQ34856875-AE623B77-9983-42D6-869F-CE202C25604AQ34972916-6833DCAD-C713-4ED2-BC6C-8C98B34C71FFQ35037678-30DB6F3C-36CD-4987-9BEB-8D5D542B7655Q35043113-6A0FE175-14D4-4D5C-A195-36B5E5888010Q35079386-66C55F92-20FD-467B-8AD5-47224F8AA9F1Q35125382-7E08EC64-6288-4D97-A582-A6D4629CB7EDQ35190925-B9BCC73C-C5B7-42DA-BC57-8258075BF6C5Q35641792-88490DC1-E4A5-4D7C-9DA8-AB4833E74BC8Q35835489-D14B3030-A605-4E39-AA95-F591CBCDAF5DQ35843507-BA504695-9E68-4CE1-9C49-0ED0588AEFE7Q35866682-B0035773-B354-41F5-A408-37978C1C829DQ35988030-4DE8FE80-3DAE-49D0-A9E2-873B0EC5387FQ36028423-E01E42C2-44B5-43E4-AFC8-5B54DD93CA26Q36057468-E6024670-8530-476A-B0D5-7A67171F0D06Q36111571-733A7562-EA3F-4655-8F37-A7CDED4B38A2Q36121743-306AFA43-F667-42E1-9461-DD4728DE2DAAQ36150517-66F8A52E-BE8D-4332-B412-88B28012ECA3Q36198661-5B6C4976-8F28-4CBC-8FFC-EA4D98A4D6BAQ36229277-D616AA1B-0AD5-4D04-8472-97447D4DA23CQ36292615-BF25C250-88E7-49BF-A235-1A9D4640ADC3
P2860
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Self antigens expressed by sol ...... implications for immunotherapy
@ast
Self antigens expressed by sol ...... implications for immunotherapy
@en
type
label
Self antigens expressed by sol ...... implications for immunotherapy
@ast
Self antigens expressed by sol ...... implications for immunotherapy
@en
prefLabel
Self antigens expressed by sol ...... implications for immunotherapy
@ast
Self antigens expressed by sol ...... implications for immunotherapy
@en
P2093
P2860
P356
P1476
Self antigens expressed by sol ...... implications for immunotherapy
@en
P2093
A Zakarian
B Odermatt
D E Speiser
K McKall-Faienza
M F Bachmann
P S Ohashi
R M Zinkernagel
P2860
P304
P356
10.1084/JEM.186.5.645
P407
P577
1997-08-01T00:00:00Z